+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 0 - 39Weeks
All Genders
ID06462235

Evaluating Aztreonam-Avibactam for Safety and Pharmacokinetics in Hospitalized Newborns and Infants With Gram-Negative Bacterial Infections

Led by Pfizer · Updated on 2026-10-15

48

Participants Needed

32

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and pharmacokinetics of a combination antibiotic medicine called aztreonam-avibactam ATM-AVI for treating infections caused by gram-negative bacteria in newborns and infants up to 9 months old who are hospitalized. The study is a Phase 2a, open-label, non-randomized trial conducted in multiple centers. It includes preterm and full-term infants divided into four age cohorts, focusing on how the medicine behaves and its effects in this young population. The study has two parts Part A and Part B. In Part A, participants receive a single 3-hour intravenous infusion of ATM-AVI to study the safety and pharmacokinetics of one dose. Part B involves multiple 3-hour intravenous infusions every 6 to 8 hours for 3 to 14 days as treatment for suspected or confirmed gram-negative bacterial infections. Participants with complicated intra-abdominal infections may also receive intravenous metronidazole, and additional antibiotics may be given for gram-positive bacteria if needed. Some participants may switch to oral antibiotics after at least 72 hours of intravenous treatment if clinically appropriate. Participants will undergo blood level assessments of ATM-AVI during and after dosing to monitor pharmacokinetics. Safety will be observed for 48 hours after the single infusion in Part A, with a follow-up safety call 4 to 5 weeks later. In Part B, clinical response will be evaluated at the end of intravenous and oral treatment and again 7 to 14 days after treatment ends. An independent committee will monitor safety throughout. Total participation lasts about 5 weeks for Part A and up to 7 weeks for Part B, including follow-up assessments.

CONDITIONS

Brief Title

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here